First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash ...

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026Zipalertinib rolling NDA ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the three months and full ...

An exhibit in the lobby of Green Library’s east wing titled “Undergraduate Showcase: The Senior Reflection in Biology” ...

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 ...

A new study led by Pierre Close's team (GIGA, Laboratory of Cancer Signaling, and WELRI Investigator) reveals how subtly ...

Taking aim at the leading risk factor for cancer, The Mark Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation (SWCRF) today announced $2.5 million to support science at ...

German agrichemical giant Bayer said Tuesday its subsidiary Monsanto had proposed a class settlement of up to $7.25 billion to settle claims that the Roundup weedkiller causes blood cancer, ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

A Silicon Valley-based company’s innovative blood test, designed to identify cancer early, hit the market five years ago and even cameoed in a recent Super Bowl ad. But new results from a large ...

York, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- WellSpan Health and Cancer Care Associates of York (CCAY) today announced a strategic partnership that will advance world-class cancer care for patients ...